Lupin share price rose 0.7 percent to hit a 52-week high of Rs 1,441.75 in the early trade on January 19 after the company received the nod of the United States Food and Drug Administration (US FDA) to launch a drug for gout, the latest in a string of approvals to sell its products in the American market.
Febuxostat tablets are indicated for chronic hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable, the company said.
At 9.18 am, Lupin was quoting at Rs 1,435.50 on BSE, up Rs 10.40, or 0.73 percent, from the previous close.
The drug will be manufactured at Lupin’s Pithampur facility.
Catch all market action in our live blog
The nod comes barely five days after the American regulator allowed the company to sell Propranolol Hydrochloride Extended-Release Capsules USP, 60 mg, 80 mg, 120 mg, and 160 mg.
The company also launched Bromfenac Ophthalmic Solution, 0.07 percent, used in the treatment of postoperative inflammation and in the reduction of ocular pain in patients who have undergone cataract surgery.
The company has also received the FDA go-ahead for dapagliflozin and saxagliptin tablets, which are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
